Genomic Selection Articles & Analysis: Older
5 news found
QN-302 (previously known as SOP1812) is the Company’s genomic quadruplex (G4)-selective transcription inhibitor platform being developed as a potential treatment for pancreatic ductal adenocarcinoma (PDAC), in addition to other tumors of high unmet clinical need. ...
Professor Neidle is a world-renowned scientist at University College London and is the key innovator of the Company’s in-licensed genomic quadruplex (G4)-selective transcription inhibitor platform. Qualigen is developing this platform’s lead compound, now called QN-302, as a potential treatment for pancreatic ductal adenocarcinoma (PDAC), which ...
These highly influential DNA markers, in combination with thousands of markers that have a small effect, would allow efficient improvements through genomic selection. This is not the first time genomic selection has been used to strengthen disease resistance. Troutlodge was the first to use genomic ...
In order to bring them together in a cow in the best and fastest way possible, genomic selection is important for breeding organisations such as CRV, and by means of genome analysis we want to improve this further", says Veerkamp. Bull genome The genome of a bull consists of 3 billion ‘letters’. ...
The molecular breeding laboratory is also developing innovative genomic selection methods which incorporate genome-wide DNA marker information in a training population which enables accurate prediction of breeding gain. Through genomic selection, SGB will shorten the breeding cycle and significantly increase the ...